Radium-select study for advanced prostate cancer
Part of Kidney & urinary clinical trials.
This trial tests a new imaging approach (radium-based) for men with prostate cancer that has spread to the bones and is getting worse. It aims to see if this helps better target treatment and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer (adenocarcinoma type) that has spread to the bone.
- Your cancer has worsened after previous treatments, shown by rising PSA or new spots on scans.
- You have at least 2 areas of cancer in your bones on a bone scan.
- You are receiving hormone therapy and bone-strengthening medication (or are willing to keep taking them).
- Your blood counts are adequate: hemoglobin above 10 and platelets above 100.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a new radioactive drug that targets PSMA, a protein on prostate cancer cells, to see if it can shrink tumors and slow the disease. It may be an option for men with advanced prostate cancer that has not responded to hormone therapy and possibly chemotherapy.
This study looks at whether differences in a cancer’s DNA repair system can predict how well radium-223 works for men with prostate cancer that has spread to the bones. It may help researchers choose better treatment for people with bone metastatic, castration-resistant prostate cancer.
This trial studies whether adding a testosterone-related therapy (BAT) to radium-223 can better control prostate cancer that has spread mainly to the bones. It may help shrink tumors in the bone and slow PSA rises, which are a common marker of prostate cancer activity.
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
This trial tests a drug called radium-223 for prostate cancer that has spread to the bonescars. It's for people who have already had a standard combination treatment and need another option. The goal is to see if adding radium-223 can help control the disease.
This study uses a special type of scan (quantitative SPECT) to measure how Radium-223 (Xofigo) works in your bones. It helps doctors better understand treatment for prostate cancer that has spread to the bones.
Hear when a new mCRPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.